Antineoplaston Therapy in Treating Patients With Metastatic Prostate Cancer
Status:
Terminated
Trial end date:
1999-12-31
Target enrollment:
Participant gender:
Summary
Current therapies for Metastatic Pancreatic Cancer provide very limited benefit to the
patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove
beneficial in the treatment of Metastatic Pancreatic Cancer.
PURPOSE: This study is being performed to determine the effects (good and bad) that
Antineoplaston therapy has on patients with Metastatic Pancreatic Cancer.